Trial of Cell Based Therapy for DMD

Eligibility Criteria

• * Duchenne muscular dystrophy, diagnosed by mutations in the DMD (dystrophin) gene and/or absence of immunohistochemical staining for dystrophin on muscle biopsy
• * Non-ambulatory
• * Intact extensor digitorum brevis (EDB) muscles bilaterally
• * Off investigational therapies for \> 30 days
• * Age 18 years of age or older at the time of consent
• * Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to enrollment (28 days for cardiac and pulmonary function):
• * Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) while receiving the study product and for 3 months after stopping tacrolimus therapy.
• * Ability to follow commands sufficiently to perform voluntary aspects of outcome measures throughout the study period
• * Willing to consent to monitoring for 15 years, including an extension period, as required for all interventional studies involving the transplantation of cells that have been genetically modified
• * Voluntary written consent from the subject or parent(s)/guardian(s) and assent from participant prior to the performance of any research related activity.
• * Presence of HLA antibodies directed toward HLA antigens on MyoPAXon
• * Active treatment with another investigational therapy
• * Known allergy to MyoPAXon components